ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 934

Interleukin-12B Is Up-Regulated By Decoy Receptor 3 In Specifically Rheumatoid Synovial Fibroblasts

Koji Fukuda1, Yasushi Miura1,2, Toshihisa Maeda1, Shinya Hayashi3 and Masahiro Kurosaka3, 1Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan, 2Department of Rehabilitation Science, Kobe University Graduate School of Health Sciences, Kobe, Japan, 3Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: cytokines, Gene Expression, Inflammation, pathogenesis and synovial cells, rheumatoid arthritis, synovial fluid

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis I

Session Type: Abstract Submissions (ACR)

Background/Purpose: Decoy receptor 3 (DcR3) is a secreted decoy tumor necrosis factor receptor and competitively binds and inhibits the TNF family including Fas-ligand (FasL), LIGHT, and TL1A. DcR3 is overexpressed in tumor cells and might benefit tumors by helping them to avoid cytotoxic and regulatory effects of the ligands. We previously reported that DcR3 overexpressed in rheumatoid synovial fibroblasts (RA-FLS) stimulated by TNFα protects the cells from Fas-induced apoptosis. We recently reported that DcR3 induces VLA-4 expression in THP-1 macrophages to inhibit cycloheximide-induced apoptosis, and that DcR3 binds to TL1A expressed on RA-FLS resulting in the negative regulation of cell proliferation induced by inflammatory cytokines. Therefore, DcR3 may regulate gene expressions in RA-FLS by binding to TL1A on RA-FLS as a ligand. In the present study, we studied interleukin (IL)-12B as one of the key molecules in DcR3-TL1A signaling in RA-FLS based on the genes expression profiles regulated by DcR3.

Methods: Microarray assay. Four individual lines of primary cultured RA-FLS were incubated with either recombinant human DcR3-Fc protein or control IgG1 for 12 hours. Gene expressions were detected by microarray assay and the profiles were analyzed. Real-time polymerase chain reaction (real-time PCR). RA and osteroarthritis (OA) -FLS were stimulated with various concentration of DcR3-Fc or control IgG1 for 12 hours. Further, RA-FLS were incubated with DcR3-Fc for 12 hours after overnight pre-incubation with anti-TL1A antibody. The relative expression levels of IL-12B mRNA were quantified by real-time PCR. Western blotting. RA-FLS was stimulated with DcR3-Fc or control IgG1 for 24 hours. The expression of IL-12B p40 protein in RA-FLS was investigated by western blotting.

Results: Microarray data analysis revealed that DcR3 up-regulates or down-regulates the expression of various genes n RA-FLS. Among the most significantly regulated 100 genes by DcR3, 45 genes were up-regulated and 55 genes were down-regulated. The profiles indicated that shared p40 subunit (IL-12B) of IL-12 and IL-23 was up-regulated by DcR3-Fc (fold change 1.65). Real-time PCR revealed that DcR3-Fc significantly increased the expression of IL-12B mRNA in RA-FLS in a dose dependent manner (113% with 10ng/ml, 135% with 100ng/ml, and 218% with 1000ng/ml) compared with control IgG1. In contrast, DcR3-Fc did not increase IL-12B mRNA in OA-FLS. Anti-TL1A antibody inhibited the up-regulation of IL-12B expression in RA-FLS induced by DcR3-Fc. Western blotting confirmed that IL-12B p40 protein in RA-FLS was increased when stimulated with DcR3-Fc.

Conclusion: IL-12 consisted of IL-12A (p35) and IL-12B induces Th1 immune responses. Meanwhile, IL-23 consisted of IL-23A (p19) and IL-12B is involved in the inflammatory pathway via IL-17. In this study, we revealed that DcR3 increased the expression of IL-12B in RA-FLS in a disease-specific fashion by binding to membrane-bound TL1A as a ligand. DcR3 may affect the pathogenesis of RA through IL-12B.


Disclosure:

K. Fukuda,
None;

Y. Miura,
None;

T. Maeda,
None;

S. Hayashi,
None;

M. Kurosaka,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/interleukin-12b-is-up-regulated-by-decoy-receptor-3-in-specifically-rheumatoid-synovial-fibroblasts/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology